BiotechTube

Prasugrel (CS-747) + Clopidogrel

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cardiovascular Diseases

Conditions

Cardiovascular Diseases, Heart Diseases

Trial Timeline

Apr 1, 2003 → Jan 1, 2004

NCT ID
NCT00059215

About Prasugrel (CS-747) + Clopidogrel

Prasugrel (CS-747) + Clopidogrel is a phase 2 stage product being developed by Eli Lilly for Cardiovascular Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00059215. Target conditions include Cardiovascular Diseases, Heart Diseases.

What happened to similar drugs?

9 of 20 similar drugs in Cardiovascular Diseases were approved

Approved (9) Terminated (2) Active (9)
🔄polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
🔄Dulaglutide + PlaceboEli LillyPhase 3
🔄raloxifene + placeboEli LillyPhase 3
🔄Orforglipron + PlaceboEli LillyPhase 3
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00059215Phase 2Completed

Competing Products

20 competing products in Cardiovascular Diseases

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
LexiscanAstellas PharmaPhase 2
35
mirabegron + tamsulosinAstellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
Lorcaserin hydrochloride + PlaceboEisaiApproved
43
Lepodisiran Sodium + PlaceboEli LillyPhase 3
44
Retatrutide + PlaceboEli LillyPhase 3
44
Empagliflozin + PlacebosEli LillyApproved
43
Evacetrapib + PlaceboEli LillyPhase 3
32
Placebo + AZD0780AstraZenecaPhase 2
35
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
26
Midazolam + AZD5718AstraZenecaPhase 1
29